uniQure (QURE)
(Delayed Data from NSDQ)
$10.12 USD
+3.45 (51.72%)
Updated Jul 10, 2024 04:00 PM ET
Pre-Market: $10.12 0.00 (0.00%) 8:24 AM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
QURE 10.12 +3.45(51.72%)
Will QURE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for QURE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QURE
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
uniQure (QURE) Soars on New Huntington's Disease Study Data
QURE: What are Zacks experts saying now?
Zacks Private Portfolio Services
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Other News for QURE
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
uniQure Shareholders Approve Board and Financial Decisions
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure’s Gene Therapy Earns FDA Advanced Therapy Designation
uniQure receives RMAT designation of AMT-130 in Huntington's Disease